Log in

NASDAQ:FBIOFortress Biotech Stock Price, Forecast & News

$2.83
+0.18 (+6.79 %)
(As of 05/25/2020 02:22 PM ET)
Add
Compare
Today's Range
$2.62
Now: $2.83
$2.89
50-Day Range
$1.83
MA: $2.17
$2.65
52-Week Range
$1.04
Now: $2.83
$3.11
Volume717,494 shs
Average Volume760,347 shs
Market Capitalization$233.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Read More
Fortress Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.63 million
Book Value$1.02 per share

Profitability

Net Income$-39,960,000.00
Net Margins-124.73%

Miscellaneous

Employees93
Market Cap$233.39 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

How has Fortress Biotech's stock been impacted by COVID-19 (Coronavirus)?

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FBIO shares have increased by 75.8% and is now trading at $2.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fortress Biotech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fortress Biotech.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fortress Biotech.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech (NASDAQ:FBIO) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.05. The biopharmaceutical company earned $12.92 million during the quarter, compared to analysts' expectations of $11.44 million. Fortress Biotech had a negative return on equity of 58.31% and a negative net margin of 124.73%. View Fortress Biotech's earnings history.

What price target have analysts set for FBIO?

5 Wall Street analysts have issued 12 month target prices for Fortress Biotech's stock. Their forecasts range from $4.00 to $19.00. On average, they anticipate Fortress Biotech's share price to reach $9.20 in the next year. This suggests a possible upside of 225.1% from the stock's current price. View analysts' price targets for Fortress Biotech.

Has Fortress Biotech been receiving favorable news coverage?

News stories about FBIO stock have been trending somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fortress Biotech earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutFortress Biotech.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 488,800 shares, a decrease of 14.1% from the April 30th total of 569,000 shares. Based on an average trading volume of 535,500 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.9% of the shares of the stock are short sold. View Fortress Biotech's Current Options Chain.

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Advanced Micro Devices (AMD), TG Therapeutics (TGTX), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Amarin (AMRN), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Dynavax Technologies (DVAX) and Geron (GERN).

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 65, Pay $532.57k)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 58, Pay $1.8M)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 66, Pay $386.35k)
  • Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. & Director (Age 54, Pay $532.57k)
  • Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.54%), Shikiar Asset Management Inc. (0.41%), FNY Investment Advisers LLC (0.22%), National Asset Management Inc. (0.10%), Jane Street Group LLC (0.07%) and Raymond James & Associates (0.05%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View institutional ownership trends for Fortress Biotech.

Which institutional investors are selling Fortress Biotech stock?

FBIO stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View insider buying and selling activity for Fortress Biotech.

Which institutional investors are buying Fortress Biotech stock?

FBIO stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Jane Street Group LLC, Raymond James & Associates, Shikiar Asset Management Inc., IHT Wealth Management LLC, Telemetry Investments L.L.C., Janney Montgomery Scott LLC, and JPMorgan Chase & Co.. View insider buying and selling activity for Fortress Biotech.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $2.83.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $233.39 million and generates $36.63 million in revenue each year. The biopharmaceutical company earns $-39,960,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Fortress Biotech employs 93 workers across the globe.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is www.fortressbiotech.com.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.